WWD.com/beauty-industry-news/financial/valeant-pharmaceuticals-to-acquire-obagi-6857255
financial
financial

Valeant Pharmaceuticals to Acquire Obagi

Under the terms of the agreement, Valeant will acquire all the outstanding common stock of Obagi for $19.75 a share in cash, or $360 million.